Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Multicenter Single-Arm Phase II Study Protocol.
Yoshihiro MiyasakaTakao OhtsukaSusumu EguchiMasafumi InomataKazuyoshi NishiharaHiroyuki ShinchiKoji OkudaHideo BabaHiroaki NaganoToshiharu UekiHirokazu NoshiroMasafumi Nakamuranull nullPublished in: International journal of surgery protocols (2021)
Strategy for borderline resectable pancreatic cancer involving arteries (BRPC-A).There is no standard regimen for neoadjuvant chemotherapy for BRPC-A.Gemcitabine plus nab-paclitaxel (GnP) shows significant tumor shrinkage.Neoadjuvant GnP for BRPC-A increases resectability and margin-negative resection.
Keyphrases
- locally advanced
- neoadjuvant chemotherapy
- phase ii
- rectal cancer
- clinical trial
- open label
- double blind
- study protocol
- squamous cell carcinoma
- radiation therapy
- advanced non small cell lung cancer
- sentinel lymph node
- placebo controlled
- randomized controlled trial
- phase iii
- cross sectional
- lymph node
- blood flow
- tyrosine kinase
- liver metastases